Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

S. Daayana, Eyad Elkord, U. Winters, M. Pawlita, R. Roden, P. L. Stern, H. C. Kitchener

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Background:Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure.Methods:We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.Results:Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens.Conclusion:The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.

Original languageEnglish
Pages (from-to)1129-1136
Number of pages8
JournalBritish Journal of Cancer
Volume102
Issue number7
DOIs
Publication statusPublished - Mar 2010
Externally publishedYes

Fingerprint

imiquimod
Vaccination
Histology
Neoplasms
T-Lymphocytes
Papillomavirus Vaccines
Human papillomavirus 18
Phase II Clinical Trials
Immunologic Factors
T-Lymphocyte Subsets
Therapeutic Uses
Regulatory T-Lymphocytes
Therapeutics
Treatment Failure
Biopsy
Antigens
Infection
Proteins

Keywords

  • Imiquimod
  • T regulatory cells
  • Therapeutic HPV vaccination
  • Vulval intraepithelial neoplasia (VIN)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. / Daayana, S.; Elkord, Eyad; Winters, U.; Pawlita, M.; Roden, R.; Stern, P. L.; Kitchener, H. C.

In: British Journal of Cancer, Vol. 102, No. 7, 03.2010, p. 1129-1136.

Research output: Contribution to journalArticle

Daayana, S. ; Elkord, Eyad ; Winters, U. ; Pawlita, M. ; Roden, R. ; Stern, P. L. ; Kitchener, H. C. / Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. In: British Journal of Cancer. 2010 ; Vol. 102, No. 7. pp. 1129-1136.
@article{215c6a844923428b852b82601f62f465,
title = "Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia",
abstract = "Background:Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure.Methods:We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.Results:Lesion response (complete regression of VIN on histology) was observed in 32{\%} (6 out of 19) of women at week 10, increasing to 58{\%} (11 out of 19) at week 20 and 63{\%} (12 out of 19) at week 52. At this time, 36{\%} (5 out of 14) of lesions showed HPV16 clearance and 79{\%} (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens.Conclusion:The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.",
keywords = "Imiquimod, T regulatory cells, Therapeutic HPV vaccination, Vulval intraepithelial neoplasia (VIN)",
author = "S. Daayana and Eyad Elkord and U. Winters and M. Pawlita and R. Roden and Stern, {P. L.} and Kitchener, {H. C.}",
year = "2010",
month = "3",
doi = "10.1038/sj.bjc.6605611",
language = "English",
volume = "102",
pages = "1129--1136",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

AU - Daayana, S.

AU - Elkord, Eyad

AU - Winters, U.

AU - Pawlita, M.

AU - Roden, R.

AU - Stern, P. L.

AU - Kitchener, H. C.

PY - 2010/3

Y1 - 2010/3

N2 - Background:Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure.Methods:We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.Results:Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens.Conclusion:The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.

AB - Background:Vulval intraepithelial neoplasia (VIN) is a premalignant condition, which is frequently associated with type HPV16 infection, and multifocal disease has high rates of surgical treatment failure.Methods:We report a phase II clinical trial of the topical immunomodulator, imiquimod, for 8 weeks, followed by 3 doses (weeks 10, 14 and 18) of therapeutic human papillomavirus (HPV) vaccination (TA-CIN, fusion protein HPV16 E6E7L2) in 19 women with VIN grades 2 and 3. Histology and HPV testing of biopsies were performed at weeks 0, 10, 20 and 52. Intralesional infiltration of T-cell subsets and lymphocyte proliferation for HPV systemic immune responses were also assessed.Results:Lesion response (complete regression of VIN on histology) was observed in 32% (6 out of 19) of women at week 10, increasing to 58% (11 out of 19) at week 20 and 63% (12 out of 19) at week 52. At this time, 36% (5 out of 14) of lesions showed HPV16 clearance and 79% (15 out of 19) of women were symptom free. At week 20, after treatment with imiquimod and vaccination, there was significantly increased local infiltration of CD8 and CD4 T cells in lesion responders; in contrast, non-responders (persistent VIN by histology) showed an increased density of T regulatory cells. After vaccination, only lesion responders had significantly increased lympho-proliferation to the HPV vaccine antigens.Conclusion:The therapeutic effect of treatment depends on the differential immune response of responders and non-responders with affect locally and systemically.

KW - Imiquimod

KW - T regulatory cells

KW - Therapeutic HPV vaccination

KW - Vulval intraepithelial neoplasia (VIN)

UR - http://www.scopus.com/inward/record.url?scp=77950370339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950370339&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605611

DO - 10.1038/sj.bjc.6605611

M3 - Article

C2 - 20234368

AN - SCOPUS:77950370339

VL - 102

SP - 1129

EP - 1136

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -